San Diego, CA – September 16, 2013 – Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today it will present the clinical data for Cynviloq™ (IG-001), which resulted in its approval as 1st line treatment of ovarian cancer by Korean FDA in March of 2013. Highlights of the findings include proof of non-inferiority of Cynviloq vs. Taxol in combination therapy with Carboplatin in patients with advanced epithelial ovarian cancer.
These data will be presented at the AACR conference on Advances in Ovarian Cancer Research: From Concept to Clinic, Miami, FL on Friday, September 20, 2013 12:30 p.m. – 2:30 p.m. at the Met Ballroom 5-7, Poster Session B, Poster Board #B67. The presentation is entitled: “IG-001 — A Non-biologic Nanoparticle Paclitaxel for the Treatment of Ovarian Cancer” authored by: Larn Hwang, Catherine Cheng, and Vuong Trieu.
